BIIB BIOGEN INC.

Price Chart

Executive Summary

UBS double-upgraded Biogen (BIIB) from Neutral to Buy on April 22, 2026, raising its price target to $225 from $185, implying 18.8% upside from the current $189.47. The call is contrarian relative to a split consensus: 43% Buy, 41% Hold, 2% Sell among 43 analysts. UBS's firm-level accuracy on BIIB is 50% (1 of 2 calls) with a +0.6% average return, below the top-tier firms like Jefferies (100% on 2 calls) and Morgan Stanley (83% on 6 calls). The $225 target is slightly above the consensus mean of $219.27 and median of $215, but well below the high of $300. Momentum is mixed: no upgrades or downgrades in the past 30 days, but EPS revisions for the current fiscal year have been cut 10 times in 30 days (from $15.61 to $13.34). Insider trades show no activity, while institutional moves are bullish — Norges Bank initiated a $464M position and FMR LLC doubled its stake (+632%). Short interest is elevated at 66.8% of float, suggesting heavy bearish positioning. The next earnings report is due July 29, 2026, about 98 days away, so no near-term catalyst. The bottom line: UBS's double upgrade is a notable contrarian signal from a below-average-accuracy firm, but the heavy short interest and downward EPS revisions warrant caution; traders should watch for a short squeeze if the stock breaks above $200.

Impact Score

Consensus & Targets

Of 43 analysts covering BIIB: 9 Strong Buy, 15 Buy (total 24 Buy, 55.8%), 18 Hold (41.9%), 1 Sell (2.3%). The consensus is tilted bullish but not overwhelmingly so — nearly half are on the sidelines. UBS's Buy call aligns with the majority but is more aggressive than the average view.

Current price: $189.47. Consensus mean PT: $219.27, median: $215, high: $300, low: $150. UBS's $225 target is 2.6% above the mean and 4.7% above the median, implying it is above-consensus bullish. Implied upside to mean: 15.7%.

Recent Analyst Activity

No analyst upgrades or downgrades in the past 30 days. EPS revisions are sharply negative: current fiscal year EPS estimates have been cut 10 times in 30 days (from $15.61 to $13.34), and next quarter estimates cut 9 times (from $4.38 to $1.94). However, next fiscal year estimates have been revised up 8 times in 30 days (from $15.99 to $16.59), suggesting a near-term trough. The divergence between near-term cuts and long-term upgrades is notable.

Firm Track Record — UBS

UBS accuracy: 55% on 5083 calls | avg return: 4.6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

UBS has a 50% accuracy rate on BIIB (1 of 2 calls) with an average return of +0.6%, placing it below average among covering firms. Top-tier firms include Jefferies (100% on 2 calls, +13% avg return), Morgan Stanley (83% on 6, +5.5%), and Piper Sandler (71% on 7, +1.6%). UBS's track record on BIIB is weak, reducing the weight of this upgrade.

Earnings Estimates

Next earnings: Jul 29, 2026

Cross-Platform Signals

Insider trades: none reported. Congressional trades: none. Institutional activity is bullish: Norges Bank initiated a $464M position, FMR LLC doubled its stake (+632%), and UBS Group AG added 35.1% to its position. Short interest is extremely high at 66.8% of float (822K shares short vs 1.23M TRF volume), indicating heavy bearish positioning. This creates potential for a short squeeze if positive catalysts emerge. The institutional buying and high short interest converge with the bullish analyst signal, amplifying the contrarian opportunity.

Documents Analyzed

Report based on filing metadata.

US Market Status